Journal of the Endocrine Society最新文献

{"title":"Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.","authors":"Marcus Vinícius Rodrigues de Souza, Marcelo Tatit Sapienza, Luciana Pinto Brito, Pedro Afonso Cortez, Suemi Marui","doi":"10.1210/jendso/bvaf016","DOIUrl":"10.1210/jendso/bvaf016","url":null,"abstract":"<p><strong>Context: </strong>Radioactive iodine (RAI) treatment is a well-established successful treatment for Graves disease (GD) but causes an increment in autoantibodies, particularly TSH receptor antibodies.</p><p><strong>Objective: </strong>To assess the performance and prognostic role of Immulite thyroid-stimulating immunoglobulin (TSI) and Elecsys thyrotropin receptor antibodies (TRAbs) immunoassays in patients with GD undergoing RAI therapy.</p><p><strong>Methods: </strong>Clinical and laboratory data of 188 patients (156 GD and 32 toxic nodule goiter), undergoing RAI therapy between January 2018 and January 2022 were prospectively collected over 12 months. Refractoriness was defined as persistent or recurrent hyperthyroidism 6 months post-RAI treatment without levothyroxine. Statistical analysis included descriptive statistics, logistic regression, and generalized estimated equations.</p><p><strong>Results: </strong>Patients had a mean age of 46.4 years, and 78.2% were women. RAI therapy was indicated in 94.2% due to uncontrolled hyperthyroidism or ATD therapy relapse (median of 35 months). Immulite TSI showed higher clinical sensitivity and accuracy (area under the curve [AUC]: 0.98, sensitivity 92.0%, accuracy 98.4%) than Elecsys TRAb (AUC: 0.97, sensitivity 82.1%, accuracy 91.2%). Successful treatment was achieved in 112 of 126 GD patients (89%). Thyroid volume, 2-hour iodine-131 uptake, free thyroxine and thyroxine levels, Elecsys TRAb, and Immulite TSI were significantly higher in the refractory group (<i>P</i> < 0.05), despite most patients receiving >300 Gy of RAI. Longitudinal thyrotropin evaluation predicted treatment response at 12 months (<i>P</i> = .01), whereas autoantibodies did not.</p><p><strong>Conclusion: </strong>Refractoriness to RAI therapy was associated with higher levels of Immulite TSI and Elecsys TRAb prior to treatment. Although AUCs for both assays were equivalent, Immulite TSI demonstrated superior clinical sensitivity and accuracy. Despite distinct autoantibody patterns emerging post-RAI, longitudinal monitoring did not predict treatment response after 1 year but indicated persistently high concentrations.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 3","pages":"bvaf016"},"PeriodicalIF":3.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing and Managing Primary Hyperparathyroidism and Fracture Risk in England: A Survey of Medical Professionals.","authors":"Kaiyang Song, Rohit Vijjhalwar, Mo Aye, Alexander N Comninos, Marian Schini, Afroze Abbas, Neil Gittoes, Muhammad Kassim Javaid","doi":"10.1210/jendso/bvae225","DOIUrl":"10.1210/jendso/bvae225","url":null,"abstract":"<p><strong>Purpose: </strong>To describe diagnostic approaches and management strategies for patients with primary hyperparathyroidism (PHPT) and recent fracture in England.</p><p><strong>Methods: </strong>We developed a survey based on a patient at high fracture risk and a new diagnosis of probable PHPT. The survey was circulated among 50 secondary care professionals identified by the Society for Endocrinology Calcium and Bone special interest group. Descriptive statistics, combinatorial, and thematic analyses were employed.</p><p><strong>Results: </strong>In the patient with hyperparathyroidism and a recent fracture, 54% of respondents favoured a 24-hour urinary calcium: creatinine clearance ratio, with 85% opting to do so after correcting vitamin D levels. Thirty-two percent (16/50) preferred the spot urinary calcium:creatinine clearance ratio, as a random test (56%, n = 9/16). Ninety-six percent of the respondents agreed they would include a fracture risk assessment in their management plan. Eighty-five percent of the respondents selected dual-energy X-ray absorptiometry scans of the lumbar spine, total hip, and femoral neck as the most popular choice. Before initiating antiosteoporotic medications (AOMs), 94% of the respondents preferred correcting vitamin D levels with diverse regimens. IV zoledronate acid was the preferred AOM, and 58% (n = 29/50) supported cinacalcet usage if the patient was ineligible for parathyroid surgery, while 26% (n = 13/50) opposed cinacalcet use entirely. No significant correlation was found between status as an endocrinology consultant or working in a tertiary care hospital and these management preferences.</p><p><strong>Main conclusion: </strong>This study of National Health Service medical staff identified highly-varied clinical practices in managing PHPT in the setting of high fracture risk, highlighting the need for pragmatic guidelines and wider education.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 2","pages":"bvae225"},"PeriodicalIF":3.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Type 2 Diabetes in Older Japanese With Similar Genetic Risk Scores: The Bunkyo Health Study.","authors":"Thu Hien Bui, Hideyoshi Kaga, Saori Kakehi, Yuki Someya, Hiroki Tabata, Yasuyo Yoshizawa, Hitoshi Naito, Tsubasa Tajima, Naoaki Ito, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Hirotaka Watada, Yoshifumi Tamura","doi":"10.1210/jendso/bvaf019","DOIUrl":"10.1210/jendso/bvaf019","url":null,"abstract":"<p><strong>Context: </strong>Genome-wide association studies have identified numerous single-nucleotide variations (SNVs, formerly single-nucleotide polymorphisms) linked to type 2 diabetes (T2D), thus improving the accuracy of genetic risk scores (GRS) in predicting T2D.</p><p><strong>Objective: </strong>This study aimed to investigate the association between the novel GRS and the prevalence of T2D and clarify the characteristics that differentiate individuals with and without T2D with similar genetic risk.</p><p><strong>Methods: </strong>This cross-sectional study analyzed 1610 Japanese individuals aged 65 to 84 years. GRS were calculated using 110 SNVs associated with T2D in Japanese, and GRS classified individuals as having low, average, or high risk for T2D. The characteristics of participants with or without diabetes were compared by sex at each risk level.</p><p><strong>Results: </strong>The prevalences of T2D were 7.8%, 14.7%, and 16.7% at low-, average-, and high-risk levels, respectively. The odds ratios at the high- and average-risk levels were significantly higher than those at the low-risk level, even after adjusting for confounding factors. The diabetes group had a higher visceral fat area (VFA) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) value, but a lower insulinogenic index, than the nondiabetes group across all risk levels. In the nondiabetes group, the II decreased significantly as GRS increased, but the HOMA-IR and Matsuda index values showed no association. In men with diabetes, VFA tended to decrease with higher GRS.</p><p><strong>Conclusion: </strong>A higher GRS was significantly associated with increased T2D prevalence in older Japanese individuals. Our data demonstrated that the contribution of VFA to the development of diabetes varies with genetic risk.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 2","pages":"bvaf019"},"PeriodicalIF":3.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetics in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency and Clinical Implications.","authors":"Paola Concolino, Henrik Falhammar","doi":"10.1210/jendso/bvaf018","DOIUrl":"10.1210/jendso/bvaf018","url":null,"abstract":"<p><p>Of all congenital adrenal hyperplasia (CAH), 95% to 99% is 21-hydroxylase deficiency (21OHD), an autosomal recessive disease. 21OHD is due to an insufficiency of 21-hydroxylase enzyme, which is encoded by the <i>CYP21A2</i> gene and involved in cortisol and aldosterone production. The clinical presentation differs widely from severe classic to mild nonclassic CAH. 21OHD represents one of the most complex and at the same time intriguing topics in human genetics and its molecular diagnosis involves ongoing challenges. To provide a meticulous presentation of the topic, we searched the past and present literature, including original articles and reviews from PubMed, ScienceDirect, Web of Science, Embase, and Scopus, using search terms for genetics of 21OHD, 21OHD variants, molecular diagnosis of 21OHD, and 21OHD genetic testing. We offer a comprehensive review focusing on recent developments, new concepts, and conclusions.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 3","pages":"bvaf018"},"PeriodicalIF":3.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemia, Insulin Sensitivity, and Secretion Improve 3 Months Post-sleeve Gastrectomy in Youth With Type 2 Diabetes.","authors":"Tyler J Dobbs, Melanie G Cree, Alex J Bailey, Amy D Baumgartner, Justin Garrish, Cecelia Diniz-Behn, Laura Pyle, Megan M Kelsey, Amy S Shah, Thomas H Inge, Petter Bjornstad, Kristen J Nadeau","doi":"10.1210/jendso/bvaf020","DOIUrl":"10.1210/jendso/bvaf020","url":null,"abstract":"<p><strong>Context: </strong>Metabolic bariatric surgery reduces weight in youth with severe obesity; however, its impacts on youth-onset type 2 diabetes (T2D) are unclear.</p><p><strong>Objective: </strong>We evaluated short-term outcomes in youth with T2D 3 months after vertical sleeve gastrectomy (VSG).</p><p><strong>Design: </strong>Longitudinal, observational study in the Impact of Metabolic surgery on Pancreatic, Renal, and cardiOVascular hEalth in youth with T2D study (IMPROVE-T2D).</p><p><strong>Setting: </strong>Academic medical university and children's hospital.</p><p><strong>Participants: </strong>Fourteen youth with T2D [mean age ± SD 16.8 ± 1.4 years; 50% female, pre-VSG hemoglobin A1c (HbA1c) 6.6 ± 0.2%; diabetes duration 17.6 ± 13.8 months; age at diabetes diagnosis 15.9 ± 1.4 years; body mass index (BMI) 46.7 ± 2 kg/m²].</p><p><strong>Interventions: </strong>Participants underwent a mixed-meal tolerance test (MMTT), body composition, and indirect calorimetry before and 3 months after VSG.</p><p><strong>Main outcomes: </strong>Glycemic control (HbA1c, diabetes medications), insulin sensitivity (Matsuda Index, Homeostasis Model of Insulin Sensitivity, oral minimal model), and secretion (C-peptide model).</p><p><strong>Results: </strong>After VSG, weight and BMI decreased (25.2 ± 5.6 kg [19%], -8.7 ± 2 kg/m² [18%], respectively, <i>P</i> < .001). Body fat decreased (4.5%, <i>P</i> = .012), with reductions of 14.1 ± 5.4 kg of fat mass (<i>P</i> = .005) and 4.5 kg of fat-free mass (<i>P</i> = .034). HbA1c decreased from 6.6 ± 0.2% to 5.7 ± 0.2% (<i>P</i> = .003), with 86% of participants no longer requiring diabetes medications. Glucose was lower throughout the MMTT, with insulin, C-peptide, free fatty acids, glucagon-like peptide-1, and peptide-YY significantly changing postsurgery (<i>P</i> < .05 for all). Insulin sensitivity and insulin secretion rate during the MMTT significantly improved.</p><p><strong>Conclusion: </strong>Three months post-VSG, youth showed significant improvements in weight, body composition, insulin sensitivity and secretion, and glycemic control, with most no longer requiring diabetes medications.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 3","pages":"bvaf020"},"PeriodicalIF":3.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Stress During Late Pregnancy and Infant Body Composition at 1 Month.","authors":"Xiaoran Yang, Sandrah P Eckel, Luis E Maldonado, Tingyu Yang, Xinci Chen, Mario Vigil, Claudia M Toledo-Corral, Genevieve F Dunton, Brendan H Grubbs, Laila Al-Marayati, Deborah Lerner, Nathana Lurvey, Rima Habre, Shohreh F Farzan, Theresa M Bastain, Carrie Breton","doi":"10.1210/jendso/bvae222","DOIUrl":"10.1210/jendso/bvae222","url":null,"abstract":"<p><strong>Context: </strong>Worldwide, obesity remains one of the most challenging crises with children being one of the most susceptible populations. The effect of maternal stress during pregnancy on newborn body composition, measured by fat mass and lean mass has, not been extensively studied.</p><p><strong>Objectives: </strong>We evaluated the association between perceived stress during late pregnancy and infant adiposity at 1 month and assessed effect modification by infant sex and preterm birth.</p><p><strong>Methods: </strong>Mother-infant dyads (N = 138) were included from the ongoing MADRES cohort. Maternal perceived stress during late pregnancy was measured by the 10-item Perceived Stress Scale (PSS), as a cumulative score, during the third trimester. Infant adiposity measures, collected at 1 month by EchoMRI, included weight, fat mass (FM), and lean mass with FM-related ratios derived. Multivariable linear regression models with interaction terms were performed.</p><p><strong>Results: </strong>Most mothers reported low to moderate stress (mean ± SD PSS: 13.2 ± 5.6) during late pregnancy. A 1-SD higher PSS was associated with higher FM% (FM (g)/weight (g): β = 0.78%; 95% CI, 0.13-1.44) but we did not find significant associations for the other adiposity measures. Statistically significant effects of perceived stress on FM-related measures were observed in male infants and preterm infants (both <i>P</i> for interaction <.05) but were null among female infants or term infants.</p><p><strong>Conclusion: </strong>In this predominately low-income Hispanic population, perceived stress during late pregnancy was associated with higher FM-related body composition measures during early infancy; this association was stronger among male and preterm infants compared to the overall population and other subgroups.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 2","pages":"bvae222"},"PeriodicalIF":3.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetics and Epigenetics of Human Pubertal Timing: The Contribution of Genes Associated With Central Precocious Puberty.","authors":"Ana Pinheiro Machado Canton, Delanie Bulcao Macedo, Ana Paula Abreu, Ana Claudia Latronico","doi":"10.1210/jendso/bvae228","DOIUrl":"10.1210/jendso/bvae228","url":null,"abstract":"<p><p>Human puberty is a dynamic biological process determined by the increase in the pulsatile secretion of GnRH triggered by distinct factors not fully understood. Current knowledge reveals fine tuning between an increase in stimulatory factors and a decrease in inhibitory factors, where genetic and epigenetic factors have been indicated as key players in the regulation of puberty onset by distinct lines of evidence. Central precocious puberty (CPP) results from the premature reactivation of pulsatile secretion of GnRH. In the past decade, the identification of genetic causes of CPP has largely expanded, revealing hypothalamic regulatory factors of pubertal timing. Among them, 3 genes associated with CPP are linked to mechanisms involving DNA methylation, reinforcing the strong role of epigenetics underlying this disorder. Loss-of-function mutations in Makorin Ring-Finger Protein 3 (<i>MKRN3</i>) and Delta-Like Non-Canonical Notch Ligand 1 (<i>DLK1</i>), 2 autosomal maternally imprinted genes, have been described as relevant monogenic causes of CPP with the phenotype exclusively associated with paternal transmission. <i>MKRN3</i> has proven to be a key component of the hypothalamic inhibitory input on GnRH neurons through different mechanisms. Additionally, rare heterozygous variants in the Methyl-CpG-Binding Protein 2 (<i>MECP2</i>), an X-linked gene that is a key factor of DNA methylation machinery, were identified in girls with sporadic CPP with or without neurodevelopmental disorders. In this mini-review, we focus on how the identification of genetic causes of CPP has revealed epigenetic regulators of human pubertal timing, summarizing the latest knowledge on the associations of puberty with <i>MKRN3</i>, <i>DLK1</i>, and <i>MECP2</i>.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 2","pages":"bvae228"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11746960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injectable Estradiol Dosing Regimens in Transgender and Nonbinary Adults Listed as Male at Birth.","authors":"Maralee Kanin, Margaret Slack, Reema Patel, Kuan-Ting Chen, Nicholas Jackson, Kristen C Williams, Shira Grock","doi":"10.1210/jendso/bvaf004","DOIUrl":"10.1210/jendso/bvaf004","url":null,"abstract":"<p><strong>Context: </strong>Many transgender and nonbinary (TGNB) individuals assigned male at birth (AMAB) seek hormone therapy to achieve physical and emotional changes. Standard therapy includes estradiol, with or without an antiandrogen. Our clinical observations suggest that currently recommended injectable estradiol dosing may lead to supratherapeutic estradiol levels.</p><p><strong>Objective: </strong>We sought to evaluate whether lower-than-recommended doses of injectable estradiol were effective in achieving serum estradiol and testosterone goals.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study to evaluate injectable estradiol dosing in treatment-naive AMAB individuals initiating hormone therapy. Data from a single provider at an academic center from January 2017 to March 2023 were analyzed. A total of 29 patients were eligible for inclusion. The primary variables of estradiol dosage, serum estradiol, and testosterone levels were analyzed over 15 months.</p><p><strong>Results: </strong>The average estradiol dose decreased from 4.3 to 3.7 mg weekly (<i>P</i> < .001) during the study period with a final on-treatment estradiol level of 248 pg/mL. All individuals achieved a testosterone level of less than 50 ng/dL during the study period. The average initial on-treatment testosterone level was not significantly different from average final on-treatment measurement of 24.0 mg/dL (<i>P</i> = .95). Spironolactone use at study initiation was not associated with a lower initial on-treatment testosterone level, though it was associated with a lower estradiol level of 285 pg/dL compared to 427 pg/dL for those on estradiol monotherapy (<i>P</i> = .017).</p><p><strong>Conclusion: </strong>Lower doses of injectable estradiol can achieve therapeutic estradiol levels with excellent testosterone suppression. Spironolactone was not associated with additional testosterone suppression and may result in lower estradiol levels.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 5","pages":"bvaf004"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurements of Iodination in Thyroglobulin: A Step Toward the Next Generation of Thyroid Cancer Monitoring.","authors":"Anthony Maus, Chris Thompson, Stefan K G Grebe","doi":"10.1210/jendso/bvaf015","DOIUrl":"10.1210/jendso/bvaf015","url":null,"abstract":"<p><p>Thyroglobulin (Tg) is a 330-kDa homodimeric protein that that is the prohormone of thyroid hormones triiodothyronine (T3) and thyroxine (T4). The most critical steps of thyroid hormone synthesis by Tg are iodination and fusion of specific tyrosine residues that are in close proximity to each other in the folded Tg protein. The degree of Tg iodination has been studied widely to determine if it is correlated with thyroid autoimmune disease with mixed results, but these efforts have been limited by the lack of an effective quantitative technique. Simultaneously, the treatment of thyroid cancer has undergone a shift toward partial thyroidectomies, thus undermining the value of Tg measurements. A possible alternative to established monitoring techniques is measurement of Tg iodination states as it has been shown that tumor-derived Tg has significantly lower iodine content. Such measurements require a thorough understanding of normal iodination status. In this study, state-of-the-art liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrumentation is used to perform bottom-up proteomics experiments and identify iodinated residues within commercially available Tg. Using this technique, sequence coverages greater than 90% were achieved, which resulted in identification of previously identified and novel hormone synthesis and donor sites. Based on the results of these discovery experiments, 5 iodination sites were selected for targeted quantitative LC-MS/MS measurements, which suggested that hormone synthesis occurs predominantly at Y24 and Y2766. The results presented herein lay the foundation for routine measurements of iodinated residues, which has the potential to overcome the limitations of current monitoring techniques and benefit patient care.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 3","pages":"bvaf015"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Acute Exercise and Carbohydrate Intake on Plasma GDF-15 Levels and Its Association With Appetite Regulation.","authors":"Ellen James, James Frampton, Kevin G Murphy, Edward S Chambers","doi":"10.1210/jendso/bvaf013","DOIUrl":"10.1210/jendso/bvaf013","url":null,"abstract":"<p><strong>Background: </strong>Growth differentiation factor 15 (GDF-15) is a potential therapeutic target for obesity due to its role in appetite suppression. Although acute exercise stimulates GDF-15 secretion, its relationship with appetite regulation remains unclear. It is also unknown whether preexercise carbohydrate intake would affect GDF-15 responses. This study aimed to examine the effects of acute exercise and carbohydrate intake on GDF-15 secretion and its potential links to appetite regulation.</p><p><strong>Methods: </strong>In a secondary analysis of a randomized crossover trial, 12 healthy males completed four 120-minute trial conditions: (1) control (water) with rest, (2) control with exercise (0-30 minutes at ∼75% of maximal oxygen uptake), (3) carbohydrate (75 g maltodextrin) with rest, and (4) carbohydrate with exercise. Plasma GDF-15 levels were measured at 0, 30, 60, and 120 minutes, alongside subjective appetite ratings using visual analog scales. Energy intake was measured at the end of each trial condition with an ad libitum meal.</p><p><strong>Results: </strong>Time-averaged area under the curve analysis showed that neither exercise [34 pg/mL (95% confidence interval [CI], -2-69 pg/mL); <i>P</i> = .062) nor carbohydrate intake [10 pg/mL (95% CI, -39-58 pg/mL); <i>P</i> = .673] independently or interactively (<i>P</i> = .283) affected GDF-15 levels. Exercise induced a delayed independent increase in GDF-15 at 120 minutes [55 pg/mL (95% CI, 18-94 pg/mL); <i>P</i> = .008]. No significant associations were found between GDF-15 levels and subjective appetite ratings or energy intake.</p><p><strong>Conclusion: </strong>A 30-minute bout of high-intensity exercise induces a delayed increase in GDF-15 levels, which is not affected by carbohydrate intake. Physiological GDF-15 responses to acute exercise display no association with markers of appetite regulation.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"9 2","pages":"bvaf013"},"PeriodicalIF":3.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}